BRPI0917224A2 - formas cristalinas de um derivado de piridina - Google Patents
formas cristalinas de um derivado de piridinaInfo
- Publication number
- BRPI0917224A2 BRPI0917224A2 BRPI0917224A BRPI0917224A BRPI0917224A2 BR PI0917224 A2 BRPI0917224 A2 BR PI0917224A2 BR PI0917224 A BRPI0917224 A BR PI0917224A BR PI0917224 A BRPI0917224 A BR PI0917224A BR PI0917224 A2 BRPI0917224 A2 BR PI0917224A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- pyridine derivative
- pyridine
- derivative
- crystalline
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0814340.6A GB0814340D0 (en) | 2008-08-05 | 2008-08-05 | Anhydrous crystol form fo a pyridine derivative |
| PCT/EP2009/060089 WO2010015626A1 (en) | 2008-08-05 | 2009-08-04 | Crystalline forms of a pyridine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0917224A2 true BRPI0917224A2 (pt) | 2015-11-24 |
Family
ID=39767571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0917224A BRPI0917224A2 (pt) | 2008-08-05 | 2009-08-04 | formas cristalinas de um derivado de piridina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8093242B2 (https=) |
| EP (1) | EP2321324A1 (https=) |
| JP (1) | JP2011529942A (https=) |
| KR (1) | KR20110052686A (https=) |
| CN (1) | CN102171219A (https=) |
| AU (1) | AU2009279135B2 (https=) |
| BR (1) | BRPI0917224A2 (https=) |
| CA (1) | CA2733235A1 (https=) |
| EA (1) | EA201170300A1 (https=) |
| GB (1) | GB0814340D0 (https=) |
| IL (1) | IL210777A0 (https=) |
| MX (1) | MX2011001414A (https=) |
| WO (1) | WO2010015626A1 (https=) |
| ZA (1) | ZA201100426B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102639536B (zh) * | 2009-08-27 | 2015-03-18 | 尼尔医疗有限公司 | 吡啶衍生物的无水晶型 |
| EP3574907B1 (en) * | 2015-05-18 | 2023-08-23 | KaNDy Therapeutics Limited | A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases |
| JP7433252B2 (ja) | 2018-03-14 | 2024-02-19 | キャンディ・セラピューティクス・リミテッド | Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤 |
| KR102950227B1 (ko) | 2019-11-15 | 2026-04-08 | 칸디 테라퓨틱스 리미티드 | Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법 |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE265209T1 (de) | 1996-07-17 | 2004-05-15 | Merck & Co Inc | Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten |
| EP1394150B1 (en) * | 1999-02-24 | 2011-01-19 | F. Hoffmann-La Roche AG | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| WO2001030348A1 (en) | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| GB0203022D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| SI1643998T1 (sl) * | 2003-07-03 | 2007-12-31 | Hoffmann La Roche | Dvojni nk1/nk3 antagonisti za zdravljenje shizofrenije |
| EP1928886B1 (en) * | 2005-09-09 | 2011-04-13 | GlaxoSmithKline LLC | Pyridine derivatives and their use in the treatment of psychotic disorders |
-
2008
- 2008-08-05 GB GBGB0814340.6A patent/GB0814340D0/en not_active Ceased
-
2009
- 2009-08-04 MX MX2011001414A patent/MX2011001414A/es unknown
- 2009-08-04 WO PCT/EP2009/060089 patent/WO2010015626A1/en not_active Ceased
- 2009-08-04 JP JP2011521561A patent/JP2011529942A/ja not_active Withdrawn
- 2009-08-04 EA EA201170300A patent/EA201170300A1/ru unknown
- 2009-08-04 CN CN2009801393221A patent/CN102171219A/zh active Pending
- 2009-08-04 AU AU2009279135A patent/AU2009279135B2/en not_active Ceased
- 2009-08-04 US US13/056,775 patent/US8093242B2/en active Active
- 2009-08-04 EP EP09781468A patent/EP2321324A1/en not_active Withdrawn
- 2009-08-04 BR BRPI0917224A patent/BRPI0917224A2/pt not_active IP Right Cessation
- 2009-08-04 KR KR1020117005159A patent/KR20110052686A/ko not_active Withdrawn
- 2009-08-04 CA CA2733235A patent/CA2733235A1/en not_active Abandoned
-
2011
- 2011-01-17 ZA ZA2011/00426A patent/ZA201100426B/en unknown
- 2011-01-20 IL IL210777A patent/IL210777A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110136798A1 (en) | 2011-06-09 |
| CA2733235A1 (en) | 2010-02-11 |
| EP2321324A1 (en) | 2011-05-18 |
| MX2011001414A (es) | 2011-04-04 |
| ZA201100426B (en) | 2012-03-28 |
| US8093242B2 (en) | 2012-01-10 |
| JP2011529942A (ja) | 2011-12-15 |
| GB0814340D0 (en) | 2008-09-10 |
| IL210777A0 (en) | 2011-03-31 |
| WO2010015626A1 (en) | 2010-02-11 |
| CN102171219A (zh) | 2011-08-31 |
| AU2009279135A1 (en) | 2010-02-11 |
| EA201170300A1 (ru) | 2011-08-30 |
| AU2009279135B2 (en) | 2012-09-13 |
| KR20110052686A (ko) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2262793T3 (da) | Krystallinske former af nilotinib-hci | |
| EP2379160A4 (en) | MAKING A PLASTER | |
| EP2404918A4 (en) | pyridine | |
| BRPI0915714A2 (pt) | forma cristalina de posaconazol | |
| DK2300465T3 (da) | Imidazopyridinderivater som hæmmere af receptortyrosinkinaser | |
| EP2376493A4 (en) | DIHYDROPYRIMIDOPYRIMIDINDERIVAT | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| EP2380877A4 (en) | PYRIDINE-3-CARBONSÄUREAMIDDERIVAT | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| EP2433940A4 (en) | SPIROIMIDAZOLONDERIVAT | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| EP2336132A4 (en) | MORPHOLINPURINDERIVAT | |
| EP2397480A4 (en) | DIAZEPINEDIONEDERIVATE | |
| ATE545635T1 (de) | Substituierte n-oxidpyrazinderivate | |
| BRPI0908512A2 (pt) | elemento tubular | |
| BRPI0922652A2 (pt) | Derivados de quinazolinamida | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
| BR112012002810A2 (pt) | derivados de n1-acil-5-fluoropirimidinona | |
| EP2401281A4 (en) | PYRIMIDINPYRIMIDOINDAZOLDERIVAT | |
| PT2492266E (pt) | Derivado de 5-hidroxipirimidino-4-carboxamida | |
| BRPI1011416A2 (pt) | derivados de antraquinova novos | |
| BRPI0917224A2 (pt) | formas cristalinas de um derivado de piridina | |
| UY3860Q (es) | Reloj | |
| CU23884B1 (es) | Derivados de dibenzotiazepina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |